Fruzaqla 5 mg (Fruquintinib Capsule) 5mg

Fruzaqla 5 mg is a prescription capsule containing fruquintinib, a kinase inhibitor used in cancer treatment. It is prescribed for metastatic colorectal cancer after prior therapies. Store below 25°C and protect from moisture.

Strength

5mg

Pack Size

21s

Storage

Below 25°C

Manufacturer / TM Owner

TAKEDA PHARMACEUTICALS/ALUNBRIG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fruzaqla 5 mg (fruquintinib) is used to treat adults with metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. It may also be used after progression on anti-VEGF therapy. This medication helps slow disease progression in advanced cancer cases.

Side Effects

Fruzaqla 5 mg works by inhibiting multiple kinases involved in tumor growth and blood vessel formation. Patients may experience gastrointestinal effects such as nausea or diarrhea. Fatigue and high blood pressure are also commonly reported during treatment.

Precautions & Warnings

Keep Fruzaqla 5 mg capsules in their original blister pack until use to protect from moisture. Store below 25°C and away from direct sunlight. Handle with care and keep out of reach of children. Report any signs of bleeding, severe diarrhea, or persistent headaches to a healthcare provider.

Avoid Interactions

Fruzaqla 5 mg may interact with strong CYP3A4 inhibitors or inducers, affecting its blood levels. Avoid grapefruit products while taking this medication. Caution is advised when combining with other drugs that lower blood pressure or increase bleeding risk. Consult a healthcare professional before starting new medications.

Frequently Asked Questions

Fruzaqla 5 mg is used to treat metastatic colorectal cancer in adults who have tried other chemotherapy treatments.

Store Fruzaqla 5 mg capsules below 25°C and keep them in the original blister pack to protect from moisture.

No, avoid grapefruit products while taking Fruzaqla 5 mg as they may increase side effects.

Common side effects include nausea, diarrhea, fatigue, and high blood pressure.

Fruzaqla 5 mg is a kinase inhibitor, not a traditional chemotherapy, but it is used in cancer treatment.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.